RePORT International Highlights

Abstract Submission Deadline: August 21st, 2026 We are pleased to announce that the 16th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place October 14-15, 2026, as a virtual meeting. This abstract-driven workshop has been a leading annual meeting in the field of tuberculosis (TB) pharmacology since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for the presentation and discussion of the latest scientific developments in TB pharmacology. If you work in TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists, and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, and PhD students; and representatives from regulatory or non-governmental organizations active in the TB field. The program consists of oral presentations that will be put in perspective, with a translation to clinical care where possible, by selected experts at the end of each workshop session. In addition, there will be e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.

Grants Deadline AT MIDNIGHT CST Spring: February 1 - March 31 Fall: August 1 - September 30 The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation is seeking highly innovative and groundbreaking medical research proposals in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. The Foundation focuses on basic science and some translational - not clinical - research. All applications must be approved by the University Provost or the Vice President of Research, and should be submitted through the office of sponsored research or like office that provides institutional approval for the request. Studies selected through an internal competition are preferred. Applications submitted by an individual researcher will NOT be considered.

DEADLINE FOR ABSTRACT SUBMISSION: 7 August 2026 Registration deadline: 5 October 2026 DATE: October 14-16, 2026 in Manipal, India. Organized in partnership by Nature Medicine, Nature Microbiology, Nature Health, Nature Communications, and MAHE, this conference will bring together leading voices in infectious disease research to explore innovative solutions to global health challenges. As the world faces rising threats from emerging pathogens, climate change, and antimicrobial resistance, the event will highlight advances in surveillance, diagnostics, drug development, and vaccination strategies. Program highlights include: Disease surveillance, modelling and forecasting Antimicrobial resistance and drug development Challenges in diagnostic and screening Disease prevention strategies Future of vaccination and disease eradication Climate change and One Health approaches Pandemic preparedness

Grant schedules and submission deadlines are fixed annually. (Spring and Fall cycles) The Mathers Foundation supports basic research with translational potential in areas such as immunology, microbiome, structural biology, cancer, genetics, stem cells, and neuroscience. We fund work that can lead to major advances in scientific understanding and human health. Please refer to the website for the details.

DEADLINE FOR APPLICATION: 1 November 2026 The Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center offers a two-year Clinical Microbiology Fellowship. This fellowship offers training for doctoral-level scientists interested in acquiring knowledge and skills necessary to direct a clinical microbiology laboratory. The fellowship will provide both general training in clinical microbiology as well as specialized training for diagnostic microbiology in immunocompromised patients. The fellow will obtain training in all subspecialties of clinical microbiology and develop knowledge of both conventional and molecular diagnostic methods for identification and antimicrobial susceptibility testing of bacteria, mycobacteria, fungi, and rapid detection of viruses and parasites. Additionally, the fellow will develop skills in laboratory management, clinical consultation related to microbiology and infectious diseases and interpretation, and clinical correlation of laboratory data. A strong emphasis is also placed on laboratory research, diagnostic assays development, and outcome studies in immunocompromised patients.

The Jimmy and Rosalynn Carter Humanitarian Award is presented annually by the National Foundation for Infectious Diseases (NFID) to honor individuals whose outstanding humanitarian efforts and achievements have contributed significantly to improving global public health through domestic and/or international activities. Priority is given to contributions in the area of infectious diseases. Selection criteria include: Humanitarian service; Public education contributions; and/or Legislative or policy achievements. Nominations for the 2027 NFID Jimmy and Rosalynn Carter Humanitarian Award will open in 2027.

The Maxwell Finland Award for Scientific Achievement is presented annually by the National Foundation for Infectious Diseases (NFID) to honor scientists who have made outstanding contributions to the understanding of infectious diseases and public health. Selection criteria include: Excellence in clinical and/or research activities; Participation in the training of future leaders in the field; and Positive impact on global public health through domestic and/or international activities. Nominations for the 2027 Maxwell Finland Award for Scientific Achievement will open in 2027.

This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. This mechanism may also be used to support development of a new resource to the broader scientific community of the National Institute of Allergy and Infectious Diseases (NIAID). It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

Conference takes place October 14-16, 2026 in Manipal, India. Registration now open! Organized in partnership by Nature Medicine, Nature Microbiology, Nature Health, Nature Communications, and MAHE, this conference will bring together leading voices in infectious disease research to explore innovative solutions to global health challenges. As the world faces rising threats from emerging pathogens, climate change, and antimicrobial resistance, the event will highlight advances in surveillance, diagnostics, drug development, and vaccination strategies. Program highlights include: Disease surveillance, modelling and forecasting Antimicrobial resistance and drug development Challenges in diagnostic and screening Disease prevention strategies Future of vaccination and disease eradication Climate change and One Health approaches Pandemic preparedness

Background: Conversational chatbots are increasingly integrated into daily life, including in health-related information-seeking, decision support, social interaction, and informal caregiving contexts. These systems are now used by individuals to interpret symptoms, manage chronic conditions, make financial and health decisions, and mitigate social isolation, often without professional oversight. Use of chatbot technologies is expanding rapidly, and patterns of adoption, benefit, and risk are likely to differ across populations, contexts, and system designs. At present, there is insufficient evidence regarding the benefits and harms of chatbot use for health and well-being or to characterize unintended consequences such as misinformation, over-reliance, altered decision-making, or delayed engagement with professional care. Rigorous research is needed to understand how chatbot design (including potential built-in safeguards), chatbot use (including but not limited to context and frequency of use), and user characteristics interact to shape health-relevant outcomes. Efforts should inform safeguards, standards, and evidence-based guidance. Purpose: This topic encourages multidisciplinary research that identifies, measures, and explains the benefits and harms associated with chatbot use (both chatbot-based interventions or treatments and routine chatbot use) across a variety of populations, use cases, and settings. Of interest are studies that move beyond proof-of-concept to characterize mechanisms, safety, and impacts on behavior, decision-making, and health outcomes. Of particular interest are studies that: - Identify risk mechanisms: including automation bias, persuasive effects, misinformation exposure, behavioral dependency, and substitution for professional care, and document adverse outcomes across different chatbot designs, and health or wellbeing-related purposes. - Compare safety and performance across chatbot models, including adaptive versus static designs and varying degrees of personalization, information retrieval, or relational engagement. - Examine impacts on decision-making and autonomy: including how chatbot use influences judgment, independence, help-seeking behavior, and relationships with family, caregivers, and clinicians. - Characterize health and functional outcomes associated with patterns of use: including frequency, duration, and longitudinal engagement, with attention to cognitive, emotional, social, and behavioral consequences. - Develop and test safeguards: including monitoring strategies and design features that promote safe, ethical, secure, and beneficial use, particularly for populations at elevated risk of harm. - Ideally, studies will focus on advancing understanding of causal mechanisms driving observed or hypothesized effects and emphasize methodological rigor, appropriate comparators, and real-world relevance.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity Announcement requires that at lease 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Fogarty's new webpage 'NIH Support of International Research: Navigating NIH Public Resources' website page contains useful information for researchers. Alongside links to NIH Guide Notices and NIH extramural news resources, the page offers guidance on the newly published application and award structure for applications that request funding for international organizations (the PA-26-002 NIH Collaborative International Research Project--Parent PF5 Clinical Trial Optional).

Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder. Funding Opportunity Goal(s): To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS. Application due date: Multiple dates, see announcement.

Application due date: Multiple dates, see announcement

Application due date: Multiple dates, see announcement

Application due date: Multiple dates, see announcement

Funding Opportunity Purpose: The goal of this notice of funding opportunity (NOFO) is to address the opioid crisis and/or overdose events by supporting action-oriented research, accelerating the translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target the individual, provider, organizational, community, or system level. This initiative prioritizes replicable and scalable approaches for accelerating the routine use of effective, evidence-based prevention, treatment and recovery interventions and services. The translation of research to practice and research relevant to chronic pain comorbid with substance use is also a priority. Research may deploy a variety of methods and approaches, including but not limited to identifying and characterizing malleable factors, developing and testing interventions and implementation strategies, deploying and testing collaborative data science approaches, and/or developing and testing approaches that integrate the collaboration of researchers and decision-makers at any levels (e.g., clinical-, health system-, public health- or policy-level). Funding Opportunity Goal(s): To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS. Application due date: Multiple dates, see announcement.

The purpose of this award is to support promising graduate students as they complete their doctoral research training and transition into mentored postdoctoral career development opportunities in research areas relevant to the missions of participating NIH Institutes and Centers. This Notice of Funding Opportunity (NOFO) does not allow fellowship candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Please refer to the website for details

Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to facilitate the entry of investigators into multiple high-priority areas of substance use research, including comorbidity with HIV. The Science Track Award for Research Transition (START) Program aims to provide investigators with the opportunity to gather preliminary data that will assist them in securing future research grants and advancing their scientific careers. Funding Opportunity Goal(s): To support basic, clinical, translational, epidemiological, or intervention science in the field of substance use. To develop new skillsets, knowledge, and/or approaches for the prevention, diagnosis, and treatment of substance use, misuse, addiction, drug overdose, and related health outcomes, including HIV/AIDS. Application due date: Multiple dates, see announcement.

The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH's mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums. Support of conferences is contingent on the fiscal and programmatic interests and priorities of the individual NIH Institutes and Centers